Open an account

Propanc Biopharma

PPCB · NASDAQ

$0.321+$0.004 (+1.26%)TodayMarket closed ·
Prev close $0.317

About PPCB

Propanc Biopharma, Inc. is a development-stage healthcare company, which engages in the research and development of cancer treatments. The firm is focused on the development of novel cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. The firm has developed a rational, composite formulation of anti-cancer compounds, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its lead product candidate, PRP, is a variation upon its formulation and involves pro-enzymes, the inactive precursors of enzymes. PRP is a long-term therapy based on pancreatic proenzyme formulation to prevent tumor recurrence and metastasis. PRP is a patented, formulation consisting of two proenzymes mixed in a synergetic ratio. PRP is in the preclinical phase of development. Its drug pipeline also includes POP1.

Employees
1
Headquarters
Melbourne, Victoria
Listed
Jun 15, 2012
Sector
Health Care
Industry
Biotechnology
Website
propanc.com

PPCB key statistics

Market cap
3.32M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
354.12K
Volume
111.57K
Open price
$0.3077
High today
$0.3332
Low today
$0.3077
52 Week high
$41.25
52 Week low
$0.3109

Propanc Biopharma (PPCB) at a glance

Propanc Biopharma (PPCB) last traded at $0.321, with a market cap of 3.32M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.3077 and $0.3332. The current price is 4.3% above the day's low and 3.7% below its high.

Volume so far is 111.57K shares, below the average of 354.12K shares a day.

Over the past year Propanc Biopharma has ranged from $0.3109 to $41.25, and now sits 0% of the way up that range.

PPCB news

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

  • Avi Kapoor

    Crude Oil Moves Higher; Dollar General Shares Gain After Upbeat Q2 Earnings

  • Vandana Singh

    Revolution Medicines’ Pancreatic Cancer Drug Approval Validates Microcap Propanc Biopharma’s Breakthrough Survival Results

  • Avi Kapoor

    Nasdaq Surges 200 Points; Nvidia Posts Upbeat Q2 Results

  • 12 Health Care Stocks Moving In Tuesday's Pre-Market Session

  • 12 Health Care Stocks Moving In Wednesday's Intraday Session

  • Avi Kapoor

    Crude Oil Edges Higher; Driven Brands Posts Upbeat Earnings

  • Avi Kapoor

    Dow Jumps Over 250 Points; US Initial Jobless Claims Rise

Similar companies

Companies in the same industry as Propanc Biopharma

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.